CELLAVISION AB (publ) - Interim report for the period January 1 - March 31, 2009

   Net sales for the quarter rose by 19% to SEK 22.0 million (18.5).

   The operating profit for the period was SEK 0.9 million (1.3).

   Earnings per share for the period amounted to SEK 0.02 (0.05).

   Cash and cash equivalents amounted to SEK 14.5 million (16.1) by the end of the quarter.

   CellaVision qualified for trade on NASDAQ OMX First North Premier on February 16, 2009.

 

   The Japanese subsidiary received its first order.

   David Autry was appointed President of CellaVision North America.

   CellaVision was nominated for the SwedenBIO Award for its successes during 2008.

 

 

CellaVision in summary
(MSEK)		Jan-March 2009	Jan-March 2008	Full year 2008
Net sales		22.0	18.5	100.4
Gross profit		14.1	11.9	63.5
Operating result		0.9	1.3	13.4
Net result		0.5	1.2	13.1
Cash flow		-5.2	-0.3	3.3

 

 

"The first quarter indicates a continued strong sales growth, and we are still dedicated to our aim of furthering growth and profit in 2009," says Yvonne Mårtensson, CEO of CellaVision. "As yet, the financial crisis has not translated into a loss of orders; however, the purchasing processes tend to take longer for hospital customers. North America accounted for the majority of sales during this quarter, and Dave Autry has now been appointed President of our North American operations."

 

"It is also satisfying to report that our Japanese subsidiary received its first order in April from the hospital laboratory in Tokyo that has been evaluating the product for some time. The laboratory at Tokyo Medical Center is a good reference to have in our future penetration of the important Japanese market."

 

"Our growth is also owing to technological development. The development of a new hardware platform has reached an intense phase of prototype assembling and testing. This has resulted in increased costs, which in turn has an effect on results despite the fact the SEK 4.8 million was capitalized as expenditure for development. The main parts of these costs are now taken. A new product based on the new hardware platform will be launched in the second half of this year."

 

Yvonne Mårtensson

CEO CellaVision AB

 

 

For more information please contact: 

Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.com 

Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.com